Know Cancer

or
forgot password

Intron-A/Aldara Combination Therapy for BCC Excluding the Face and Scalp


Phase 4
N/A
N/A
Not Enrolling
Both
Basal Cell Carcinoma

Thank you

Trial Information

Intron-A/Aldara Combination Therapy for BCC Excluding the Face and Scalp


Inclusion Criteria:



- Nodular or superficial basal cell carcinoma on the skin excluding scalp or face

Exclusion Criteria:

- Pregnancy

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

resolution of basal cell carcinoma

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Stephen B Tucker, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Texas Health Science Center of Houston Dermatology Clinic

Authority:

United States: Institutional Review Board

Study ID:

HSC-MS-06-0478

NCT ID:

NCT00581425

Start Date:

December 2007

Completion Date:

September 2011

Related Keywords:

  • Basal Cell Carcinoma
  • BCC
  • Basal Cell Carcinoma
  • Intron-A
  • Aldara
  • Basal Cell Carcinoma excluding scalp and face
  • Carcinoma
  • Carcinoma, Basal Cell

Name

Location

University of Texas Health Science Center of Houston Dermatology ClinicHouston, Texas  77030